注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Sensei Biotherapeutics Inc是一家专注于发现和开发癌症疗法的免疫肿瘤公司。该公司设计了两种方法来开发治疗方法,肿瘤微环境激活生物制剂(TMAb)平台禁用肿瘤微环境中的检查点和其他免疫抑制信号,以释放现有T细胞对抗肿瘤,而ImmunoPhage平台训练新T细胞识别和杀死恶性细胞。利用TMAb平台,该公司正在开发SNS-101,这是一种人类抗体,旨在仅在低pH肿瘤微环境中选择性地阻断T细胞激活的V-结构域Ig抑制物(VISTA)检查点。该公司还利用其平台开发针对多种实体肿瘤适应症的其他临床前项目。该公司在早期开发的不同阶段有四种研究产品:SNS-101、SNS-102、SNS-103和SNS-401。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Thomas G. Ricks | 70 | 2015 | Independent Director |
William R. Ringo | 78 | 2022 | Independent Chairman |
John K. Celebi | 51 | 2018 | President, CEO & Director |
Robert Holmen | 59 | 2017 | Independent Director |
Alain Algazi | - | - | Member of Immuno-Oncology Advisory Board |
Kristian Humer | 49 | 2021 | Independent Director |
Richard J. Ulevitch | 80 | 2021 | Member of Immuno-Oncology Advisory Board |
Maura Gillison | - | 2021 | Member of Immuno-Oncology Advisory Board |
James Peyer | 37 | 2020 | Independent Director |
Sara Pai | - | - | Member of Immuno-Oncology Advisory Board |
Deneen Vojta | 59 | 2021 | Independent Director |
Jessie M. English | 60 | 2021 | Independent Director |
Robert Schreiber | - | - | Member of Immuno-Oncology Advisory Board |
Daniel H. Sterman | - | - | Member of Immuno-Oncology Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核